WEBULL
WebtradeDownload

Carl Zeiss Meditec (XTRA:AFX) Could Be 6% Overvalued As 2026 Guidance Lands

Simply Wall St · 1d ago

Carl Zeiss Meditec (XTRA:AFX) is in focus after issuing 2026 revenue guidance of about €2.15b to €2.20b, alongside planned goodwill impairment of roughly €150 million in its Ophthalmology segment for the fourth quarter.

See our latest analysis for Carl Zeiss Meditec.

The updated 2026 revenue outlook and planned €150 million goodwill impairment land at a time when Carl Zeiss Meditec’s share price has risen 22.35% over 90 days. However, the 1 year total shareholder return is still down 29.17%, pointing to a recovery in momentum after a weak longer term performance.

If this kind of rebound catches your interest, it could be a good moment to scan the market for other healthcare and ophthalmology related opportunities using the 133 healthcare AI stocks

Carl Zeiss Meditec’s shares have bounced hard while goodwill is set to be written down and 2026 guidance is on the table. Is this already a fair entry, or does waiting for a better price make more sense?

Most Popular Narrative: 6.3% Overvalued

The most followed narrative for Carl Zeiss Meditec points to a fair value of about €28.63, slightly below the last close at €30.44, and frames that gap using detailed growth and margin assumptions.

The recent approval of the VISUMAX 800 in China, earlier than expected, positions Carl Zeiss Meditec AG for potential revenue growth. The launch is expected to boost higher ASP (Average Selling Price) for both devices and treatment packs, enhancing future revenue streams.

Read the complete narrative.

Want to see what kind of revenue path and profit margins need to line up to support that valuation call? The narrative leans on a multi year earnings ramp, a steady shift toward higher value products, and a moderated future P/E that still implies solid confidence in Carl Zeiss Meditec’s business model.

Result: Fair Value of €28.63 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Carl Zeiss Meditec story still carries risk, as weaker conditions in China and past margin pressure are both capable of upsetting the current earnings path.

Find out about the key risks to this Carl Zeiss Meditec narrative.

Another View on Carl Zeiss Meditec’s Valuation

While the leading narrative for Carl Zeiss Meditec sees the stock as about 6.3% overvalued against a €28.63 fair value, the current P/E of 21.9x sends a different signal. It sits below the European Medical Equipment industry at 26.5x and below a 28.4x fair ratio, which suggests the market is pricing in some caution rather than optimism. Which signal do you think better reflects the risk you see in the story?

For a closer look at what the numbers say about this price, and how that compares to peers, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

XTRA:AFX P/E Ratio as at Aug 2026
XTRA:AFX P/E Ratio as at Aug 2026

Next Steps

If this Carl Zeiss Meditec update leaves you torn between caution and optimism, consider taking action while the details are fresh and test the numbers for yourself using the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Carl Zeiss Meditec?

If Carl Zeiss Meditec has sharpened your focus on quality opportunities, now is a smart time to broaden your watchlist using targeted stock ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.